News, stories & events
Introduction: Microbiological research plays a pivotal role in understanding the diverse microbial world and its impact on human health, the environment, various industries, and society as a whole. Collecting and transporting microbial samples accurately and efficiently is crucial for preserving…
Ruhvenile won the Biocon biologics award out of the 3000 applicants from all over India
A collaboration between Ruhvenile Biomedical, India, and RNA Smart Health, Paris, France, aims to develop RNA-based therapeutics to combat COVID-19.
A team, comprising Arockiasamy Arulandu, Sujatha Sunil, and Alessandro Marcello, together with Ruhvenile Biomedical OPC Pvt. Ltd., India, is working to develop novel therapeutics against COVID-19, through the design and synthesis of small, molecular inhibitors specifically targeting SARS-CoV-2 viral replication.
Ruhvenile has been extensively screening small organic compounds to identify non-toxic, non-ionic compounds with validated enveloped-viruses deactivation potential. One potent non-toxic, carbohydrate-based compound has been shown to deactivate different viruses.
We’re proud that BiomLife was launched by the secretary of the Department of Biotechnology, making it a significant moment for our team. It’s a testament to our innovative approach to microbiome research.
Professor Henry Daniell and Professor Thomas Muck were invited to give talks on vaccine development and the application of CRISPR technology.
Ruhvenile Biomedical organized an Innovators Meet for inculcating the necessary orientation among the startups to become successful
The Ruhvenile team met the French delegate at IIT Delhi on 6th October and is working with the French company to develop biomedical products.
Ruhvenile’s whole team is wishing you the happiest of birthdays